By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
latest_posts
- 1
Hundreds are quarantined in South Carolina as measles spreads in 2 US outbreaks - 2Tear gas and arrests: Iranian regime continues crackdown on protesters amid economic unrest
- 3Louisiana seeks California doctor’s extradition, testing the limits of shield laws
- 45 Christmas movies to stream for less with this Paramount+ Black Friday deal
- 54 astronauts depart ISS, leaving behind just 3 crewmates to staff the orbiting lab
- Wellness Bits of knowledge Readily available: A Survey of \Following Wellbeing and Progress\ Wellness Wearables
- Overlooked infertility care should be part of national health services, says WHO
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- 5 Signs Now is the ideal time to Update Your Android Telephone: When to Take the Action
- Drones, physics and rats: Studies show how the people of Rapa Nui made and moved the giant statues – and what caused the island’s deforestation
- Evidence of lost baptismal rite stage uncovered in Byzantine era cathedral near Sea of Galilee
- Manhunt for Brown University shooter continues: FBI releases photos of suspect, announces $50K reward
- 10 Hints for an Effective New employee screening
- Holiday spots Well known With Americans In 2024
